CU23549A1 - Composiciones farmacéuticas que contienen la proteína nma0939 - Google Patents
Composiciones farmacéuticas que contienen la proteína nma0939Info
- Publication number
- CU23549A1 CU23549A1 CU20050279A CU20050279A CU23549A1 CU 23549 A1 CU23549 A1 CU 23549A1 CU 20050279 A CU20050279 A CU 20050279A CU 20050279 A CU20050279 A CU 20050279A CU 23549 A1 CU23549 A1 CU 23549A1
- Authority
- CU
- Cuba
- Prior art keywords
- nma0939
- protein
- compositions
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con el campo de la medicina, particularmente con el desarrollo de composiciones farmacéuticas que contienen la proteína NMA0939. Las composiciones de la presente invención confieren protección contra diferentes enfermedades, causadas o no por patógenos. La proteína NMA0939 se identificó como componente de las preparaciones de vesículas de membrana externa de Neisseria meningitidis, se obtuvo mediante la tecnología del ADN recombinante y se evaluó su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservación del gen que codifica para la proteína NMA0939, las composiciones que la contienen poseen alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. Las composiciones de esta invención son aplicables en la medicina humana.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20050279A CU23549A1 (es) | 2005-12-29 | 2005-12-29 | Composiciones farmacéuticas que contienen la proteína nma0939 |
ARP060105777A AR058735A1 (es) | 2005-12-29 | 2006-12-26 | Composiciones farmaceuticas que contienen la proteina nma 0939 |
AU2006331224A AU2006331224A1 (en) | 2005-12-29 | 2006-12-28 | Pharmaceutical compositions containing protein NMA0939 |
EP06846929A EP1977761A2 (en) | 2005-12-29 | 2006-12-28 | Pharmaceutical compositions containing protein nma0939 |
CNA200680049521XA CN101443037A (zh) | 2005-12-29 | 2006-12-28 | 包含蛋白质nma0939的药物组合物 |
KR1020087018520A KR20080081198A (ko) | 2005-12-29 | 2006-12-28 | 단백질 nma0939를 포함하는 약학적 조성물 |
RU2008131066/13A RU2008131066A (ru) | 2005-12-29 | 2006-12-28 | Фармацевтическая композиция, содержащая белок nma0939 |
US12/097,895 US20090208521A1 (en) | 2005-12-29 | 2006-12-28 | Pharmaceutical compositions containing protein nma0939 |
BRPI0620867-3A BRPI0620867A2 (pt) | 2005-12-29 | 2006-12-28 | formulações farmacêuticas que contêm a proteìna nma0939 |
CA002633424A CA2633424A1 (en) | 2005-12-29 | 2006-12-28 | Pharmaceutical compositions containing protein nma0939 |
PCT/CU2006/000019 WO2007073705A2 (es) | 2005-12-29 | 2006-12-28 | Composiciones farmacéuticas que contienen la proteína nma0939 |
ZA200805355A ZA200805355B (en) | 2005-12-29 | 2008-06-19 | Pharmaceutical compositions containing protein NMA0939 |
NO20083318A NO20083318L (no) | 2005-12-29 | 2008-07-28 | Farmasoytiske sammensetninger inneholdende protein NMA0939 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20050279A CU23549A1 (es) | 2005-12-29 | 2005-12-29 | Composiciones farmacéuticas que contienen la proteína nma0939 |
Publications (2)
Publication Number | Publication Date |
---|---|
CU23549A1 true CU23549A1 (es) | 2010-07-20 |
CU23549B7 CU23549B7 (es) | 2010-07-20 |
Family
ID=38218331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20050279A CU23549A1 (es) | 2005-12-29 | 2005-12-29 | Composiciones farmacéuticas que contienen la proteína nma0939 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090208521A1 (es) |
EP (1) | EP1977761A2 (es) |
KR (1) | KR20080081198A (es) |
CN (1) | CN101443037A (es) |
AR (1) | AR058735A1 (es) |
AU (1) | AU2006331224A1 (es) |
BR (1) | BRPI0620867A2 (es) |
CA (1) | CA2633424A1 (es) |
CU (1) | CU23549A1 (es) |
NO (1) | NO20083318L (es) |
RU (1) | RU2008131066A (es) |
WO (1) | WO2007073705A2 (es) |
ZA (1) | ZA200805355B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180064801A1 (en) * | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066791A1 (en) * | 1999-04-30 | 2000-11-09 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
EP1961427A3 (en) * | 2002-08-02 | 2009-11-04 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccine compositions comprising a combination of antigens |
CU23236A1 (es) * | 2003-12-03 | 2007-09-26 | Ct Ingenieria Genetica Biotech | PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P |
-
2005
- 2005-12-29 CU CU20050279A patent/CU23549A1/es active IP Right Grant
-
2006
- 2006-12-26 AR ARP060105777A patent/AR058735A1/es unknown
- 2006-12-28 RU RU2008131066/13A patent/RU2008131066A/ru not_active Application Discontinuation
- 2006-12-28 CA CA002633424A patent/CA2633424A1/en not_active Abandoned
- 2006-12-28 CN CNA200680049521XA patent/CN101443037A/zh active Pending
- 2006-12-28 EP EP06846929A patent/EP1977761A2/en not_active Withdrawn
- 2006-12-28 AU AU2006331224A patent/AU2006331224A1/en not_active Abandoned
- 2006-12-28 KR KR1020087018520A patent/KR20080081198A/ko not_active Application Discontinuation
- 2006-12-28 WO PCT/CU2006/000019 patent/WO2007073705A2/es active Search and Examination
- 2006-12-28 BR BRPI0620867-3A patent/BRPI0620867A2/pt not_active IP Right Cessation
- 2006-12-28 US US12/097,895 patent/US20090208521A1/en not_active Abandoned
-
2008
- 2008-06-19 ZA ZA200805355A patent/ZA200805355B/xx unknown
- 2008-07-28 NO NO20083318A patent/NO20083318L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200805355B (en) | 2009-04-29 |
CN101443037A (zh) | 2009-05-27 |
RU2008131066A (ru) | 2010-02-10 |
AU2006331224A1 (en) | 2007-07-05 |
WO2007073705A3 (es) | 2007-09-13 |
BRPI0620867A2 (pt) | 2011-11-29 |
CU23549B7 (es) | 2010-07-20 |
NO20083318L (no) | 2008-09-26 |
KR20080081198A (ko) | 2008-09-08 |
AR058735A1 (es) | 2008-02-20 |
WO2007073705A2 (es) | 2007-07-05 |
CA2633424A1 (en) | 2007-07-05 |
US20090208521A1 (en) | 2009-08-20 |
EP1977761A2 (en) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123052T1 (el) | Συνθεσεις και μεθοδοι σχετικες με παραλλαγες της πρωτεϊνες α (spa) | |
CY1117757T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
CY1119854T1 (el) | Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου | |
MX2019005268A (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
MX2010012999A (es) | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso. | |
CU23734A1 (es) | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas | |
WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
CO6400150A2 (es) | Proteína de enlace de il-13 | |
PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
CY1113693T1 (el) | Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων | |
CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
CY1114724T1 (el) | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων | |
BRPI0606614A2 (pt) | peptìdeos para distribuição de vacinas na mucosa | |
CY1119073T1 (el) | Ισομορφες γλυκοζυλιωσης ανθρωπινης ιστικης καλλικρεινης 1 | |
CU23572A1 (es) | Composición farmacéutica que comprende la proteína nmb0938 | |
BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo | |
CU23549A1 (es) | Composiciones farmacéuticas que contienen la proteína nma0939 | |
CY1115322T1 (el) | Εκχυλισμα τριγωνελλας για τη θεραπεια νοσων στον ανθρωπο και τα ζωα στις οποιες εμπλεκονται μαστιγομορφα παρασιτα | |
CU23584A1 (es) | Composición farmacéutica que comprende la proteína nmb1796 | |
CU23575A1 (es) | Composición farmacéutica que comprende la proteína nmb0606 | |
CU23528A1 (es) | Composición farmacéutica que comprende la proteína nmb0848 | |
AR046937A1 (es) | Proteina nmb0928 y su uso en formulaciones farmaceuticas | |
MX2022001742A (es) | Metodos para prevenir el dengue y la hepatitis a. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |